DaVita Inc. (DVA)
Stock Price:
$82.46 USD
0.73 (0.89%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
10.06B |
| Revenue (ttm) |
11.52B |
| Net Income (ttm) |
829.34M |
| Shares Out |
121.80M |
| EPS (ttm) |
6.22 |
| PE Ratio |
13.26 |
| Forward PE |
13.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$82.46 |
| Previous Close |
$81.73 |
| Change ($) |
0.73 |
| Change (%) |
0.89% |
| Day's Open |
82.35 |
| Day's Range |
81.81 - 82.83 |
| Day's Volume |
781,736 |
| 52-Week Range |
53.51 - 92.16 |
More Stats
| Market Cap |
10.06B |
| Enterprise Value |
19.74B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
121.80M |
| Float |
118.52M |
| EPS (basic) |
6.3 |
| EPS (diluted) |
6.22 |
| FCF / Share |
13.50 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
7.54% |
| FCF Yield |
16.39% |
| Payout Ratio |
n/a |
| Shares Short |
5.22M |
| Short Ratio |
6.29 |
| Short % of Float |
6.31% |
| Beta |
1.23 |
| PE Ratio |
13.26 |
| Forward PE |
13.07 |
| P/FCF Ratio |
6.10 |
| PS Ratio |
0.87 |
| PB Ratio |
4.66 |
| Revenue |
11.52B |
| Operating Income |
1.69B |
| Net Income |
829.34M |
| Free Cash Flow |
1.65B |
| Net Cash |
-9.68B |
| Net Cash / Share |
-79.36 |
| Gross Margin |
30.15% |
| Operating Margin |
14.65% |
| Profit Margin |
7.20% |
| FCF Margin |
14.30% |
| ROA |
5.81% |
| ROE |
23.14% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (13)
| Buy |
3 |
| Overweight |
0 |
| Hold |
10 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$95.50*
(15.81% upside)
Low
79.0
Current: $82.46
High
105.0
Target: 95.50
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 11,388 | 11,405 | 10,877 | 10,707 | 9,982 | 12,795 | 11,764 | 8,186 | 6,732 | 6,220 |
| Revenue Growth | -0.14% | 4.86% | 1.58% | 7.27% | -21.98% | 8.76% | 43.7% | 21.61% | 8.24% | - |
| Gross Profit | 3,474 | 3,209 | 3,237 | 3,276 | 3,126 | 3,676 | 3,566 | 2,603 | 2,098 | 1,792 |
| Operating Income | 1,631 | 1,530 | 1,821 | 2,013 | 1,123 | 1,792 | 1,459 | 1,281 | 1,146 | 985 |
| Net Income | 811 | 159 | 664 | 880 | 270 | 723 | 633 | 536 | 478 | 406 |
| Shares Outstanding | 153 | 171 | 189 | 202 | 212 | 212 | 210 | 192 | 189 | 203 |
| Earnings Per Share | 5.27 | 0.92 | 3.47 | 4.29 | 1.25 | 3.33 | 2.95 | 2.74 | 2.48 | 1.97 |
| EPS Growth | 472.83% | -73.49% | -19.11% | 243.2% | -62.46% | 12.88% | 7.66% | 10.48% | 25.89% | - |
| Operating Cash Flow | 2,072 | 1,772 | 1,913 | 1,972 | 1,557 | 1,459 | 1,773 | 1,101 | 1,180 | 840 |
| Capital Expenditures | -767 | -987 | -905 | -829 | -708 | -641 | -618 | -550 | -400 | -274 |
| Free Cash Flow | 1,306 | 785 | 1,008 | 1,143 | 849 | 818 | 1,156 | 551 | 780 | 566 |
| Cash & Equivalents | 1,220 | 418 | 552 | 982 | 1,907 | 1,303 | 953 | 541 | 411 | 883 |
| Total Debt | 11,176 | 10,102 | 9,336 | 9,105 | 9,130 | 8,419 | 8,416 | 8,560 | 4,505 | 4,309 |
| Net Cash / Debt | -9,956 | -9,684 | -8,784 | -8,123 | -7,223 | -7,116 | -7,463 | -8,019 | -4,094 | -3,426 |
| Assets | 17,311 | 19,110 | 18,975 | 18,756 | 18,515 | 17,617 | 17,099 | 16,015 | 8,904 | 8,114 |
| Liabilities | 13,812 | 14,077 | 13,077 | 12,933 | 12,567 | 11,427 | 11,796 | 11,517 | 6,157 | 5,694 |
| Book Value | 2,133 | 3,703 | 4,690 | 4,648 | 4,871 | 5,171 | 4,432 | 3,763 | 2,141 | 1,978 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DaVita Inc. |
| Country |
United States |
| Employees |
65,000 |
| CEO |
Javier J. Rodriguez |
Stock Information
| Ticker Symbol |
DVA |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Specialized Health Services |
| Unique Identifier |
NYSE: DVA |
| IPO Date |
October 31, 1995 |
Description
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2019, it provided dialysis and administrative services in the United States through a network of 2,753 outpatient dialysis centers serving approximately 206,900 patients; and operated 259 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 28,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.